newsfilter
← Latest News
ACCESS Newswire·

9 Meters Biopharma, Inc. Presents Pharmacokinetic Data from Phase 1b/2a Study with Vurolenatide, Currently in Phase 2 for Short Bowel Syndrome, at the American College of Gastroenterology (ACG) 2021 Annual Scientific Meeting

- Vurolenatide's half-life is consistent with twice-monthly dosing -- Top-line results from the ongoing Phase 2 VIBRANT trial on track to be reported before year's end - RALEIGH, NC / ACCESSWIRE / October 26, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR